Cart
0
Get 20% Free Customization In This Report
Buy this report from - $3456

Blood Plasma Derivatives Market by Type (Albumin, Factor VIII, Factor IX, Immunoglobulin, Hyperimmune Globulin, and Others), Application (Hemophilia, Hypogammaglobulinemia, Immunodeficiency Diseases, von Willebrands Disease (vWD), and Other Application), and End User (Hospitals, Clinics, and Other End Users) - Global Opportunity Analysis and Industry Forecast, 2016-2023

LI_18656
Pages: 240
Apr 2018 | 3632 Views
face gplus_n
Author's : Pallavi Jaiswal & Mayuri Srivastava
Tables: 120
Charts: 48
twit_n pr_n

Blood Plasma Derivatives Market Overview:

The Global Blood Plasma Derivatives Market was valued at $23,613 million in 2016, and is projected to reach $44,333 million at a CAGR of 9.3% from 2017 to 2023. Blood plasma is the liquid component of blood constituting of water along with plasma components such as immunoglobulin, electrolytes, glucose, clotting factors, electrolytes, and hormones. It plays a crucial role in maintaining the electrolyte and osmotic balance while preventing infection and blood disorders in the body. Plasma derivatives are the concentrates of specific proteins, which require pooling of plasma from large number of donors. For instance, they require more than hundred plasma donations to produce sufficient immunoglobulin to treat an immune-deficient patient for one year. They are obtained by the process of fractionation where protein concentrates are separated and then clinically used.

Get more information on this report : Request Sample Pages

Market Dynamics

The growth of the global blood plasma derivatives market is majorly driven by increase in prevalence of life-threatening disorders, especially hemophilia. Other factors boosting the market growth include rise in adoption of blood plasma derivatives products, upsurge in geriatric population across the world, and increase in awareness about blood & plasma donation. However, factors such as high cost of plasma derivative-based therapy and post-operative risks associated with plasma replacement therapy hamper the market growth. Conversely, the development of enhanced methods for preservation of plasma derivatives along with advanced procedures for fractionation and high potential in untapped markets in the emerging economies are expected to provide lucrative growth opportunities for the market.

Market Segmentation

The global blood plasma derivatives market is segmented based on type, application, end user, and region. On the basis of type, the market is segmented into albumin, factor VIII, factor IX, immunoglobulin, hyperimmune globulin, and others. Immunoglobulin segment accounted for the largest market share in 2016, and is expected to continue this trend throughout the forecast period. On the other hand, albumin segment is anticipated to grow at a significant CAGR of 9.4% during the forecast period.

Get more information on this report : Request Sample Pages

By application, the market is categorized into hemophilia, hypogammaglobulinemia, immunodeficiency diseases, von Willebrand's Disease (vWD), and other applications. Immunodeficiency diseases segment accounted for the largest market share in 2016, whereas hemophilia segment is expected to register the highest growth rate during the forecast period.

Get more information on this report : Request Sample Pages

Depending on end user, the market is fragmented into hospitals, clinics, and other end users. Hospitals held the largest share of the market in 2016, whereas clinics segment is expected to register the highest growth rate during the forecast period.

Region wise, the market is studied across North America, Europe, Asia-Pacific, and LAMEA. North America held the largest share of the market in 2016, followed by Europe. On the other hand, Asia-Pacific is anticipated to dominate the market during the analysis period, owing to high population base, increase in disposable income, and improvement in patient awareness about plasma derivatives. Moreover, Asia is a large continent, and has emerged as an epicenter of life-threatening diseases.

Get more information on this report : Request Sample Pages

The key players of this market include Grifols, S.A., SK Plasma Co., Ltd., Fusion Health Care Pvt. Ltd., Biotest AG, Green Cross Corporation, Baxter International Inc., LFB S.A., Octapharma AG, CSL Limited, and Shire Plc.

Other players (these players are not profiled in the report and the same can be included on request) in the value chain include China Biologic Products, Inc., Kedrion Biopharma, Inc., BDI Pharma, Inc., Bayer AG, and Hualan Biological Engineering, Inc.

Key Benefits

  • The study provides an in-depth analysis of the global blood plasma derivatives market with current trends and future estimations from 2016 to 2023 to elucidate the imminent investment pockets.
  • Comprehensive analysis of factors that drive and restrict the market growth is provided.
  • Identification of factors instrumental in changing the market scenario, rise in opportunities, and identification of key companies that can influence this market on a global & regional scale are provided.
  • Key players are profiled and their strategies are analyzed thoroughly to understand the competitive outlook of the market.

Blood Plasma Derivatives Market Key Segments:

By Type

  • Albumin
  • Factor VIII
  • Factor IX
  • Immunoglobulin
  • Hyperimmune Globulin
  • Others        

By Application

  • Hemophilia
  • Hypogammaglobulinemia
  • Immunodeficiency Diseases
  • von Willebrand's Disease (vWD)
  • Other Application

By End User

  • Hospitals
  • Clinics
  • Other End Users

By Region

  • North America
    • U.S.
    • Canada
    • Mexico
  • Europe
    • Germany
    • France
    • UK
    • Italy
    • Spain
    • Rest of Europe
  • Asia-Pacific
    • China
    • Japan
    • India
    • Australia
    • South Korea
    • Rest of Asia-Pacific
  • LAMEA
    • Brazil
    • Saudi Arabia
    • South Africa
    • Rest of LAMEA
 

Chapter: 1: INTRODUCTION

1.1. Report description
1.2. Key benefits for stakeholders
1.3. Key market segments

1.3.1. By Type
1.3.2. By Application
1.3.3. By End User
1.3.4. By Region
1.3.5. List of key players profiled in the report

1.4. Research methodology

1.4.1. Secondary research
1.4.2. Primary research
1.4.3. Analyst tools and models

Chapter: 2: EXECUTIVE SUMMARY

2.1. Key findings of the study
2.2. CXO perspective

Chapter: 3: MARKET OVERVIEW

3.1. Market definition and scope
3.2. Key findings

3.2.1. Top investment pockets
3.2.2. Top winning strategies

3.3. Top player positioning
3.4. Market dynamics

3.4.1. Drivers

3.4.1.1. High prevalence of life threatening diseases
3.4.1.2. Growth in awareness about blood and plasma donation
3.4.1.3. Rise in geriatric population
3.4.1.4. High adoption of blood plasma derivatives

3.4.2. Restraints

3.4.2.1. High cost of blood plasma derivatives based therapy
3.4.2.2. Risks associated with plasma derivatives

3.4.3. Opportunities

3.4.3.1. Development of better methods for plasma derivatives manufacturing
3.4.3.2. Opportunities in emerging economies

3.4.4. Impact analyses

3.5. Government regulations

3.5.1. Plasma derivatives regulations in United States and Europe

Chapter: 4: BLOOD PLASMA DERIVATIVES MARKET, BY TYPE

4.1. Overview

4.1.1. Market size and forecast

4.2. Albumin

4.2.1. Key market trends, growth factors and opportunities
4.2.2. Market size and forecast, by region
4.2.3. Market analysis, by country

4.3. Factor VIII

4.3.1. Key market trends, growth factors and opportunities
4.3.2. Market size and forecast, by region
4.3.3. Market analysis, by country

4.4. Factor IX

4.4.1. Key market trends, growth factors and opportunities
4.4.2. Market size and forecast, by region
4.4.3. Market analysis, by country

4.5. Immunoglobulin

4.5.1. Key market trends, growth factors and opportunities
4.5.2. Market size and forecast, by region
4.5.3. Market analysis, by country

4.6. Hyperimmune globulin

4.6.1. Key market trends, growth factors and opportunities
4.6.2. Market size and forecast, by region
4.6.3. Market analysis, by country

4.7. Others

4.7.1. Key market trends, growth factors and opportunities
4.7.2. Market size and forecast, by region
4.7.3. Market analysis, by country

Chapter: 5: BLOOD PLASMA DERIVATIVES MARKET, BY APPLICATION

5.1. Overview

5.1.1. Market size and forecast (value)

5.2. Hemophilia

5.2.1. Market size and forecast, by region
5.2.2. Market analysis, by country

5.3. Hypogammaglobulinemia

5.3.1. Market size and forecast, by region
5.3.2. Market analysis, by country

5.4. Immunodeficiency diseases

5.4.1. Market size and forecast, by region
5.4.2. Market analysis, by country

5.5. von Willebrand's disease (vWD)

5.5.1. Market size and forecast, by region
5.5.2. Market analysis, by country

5.6. Other application

5.6.1. Market size and forecast, by region
5.6.2. Market analysis, by country

Chapter: 6: BLOOD PLASMA DERIVATIVES MARKET, BY END USER

6.1. Overview

6.1.1. Market size and forecast

6.2. Hospitals

6.2.1. Market size and forecast, by region
6.2.2. Market analysis, by country

6.3. Clinics

6.3.1. Market size and forecast, by region
6.3.2. Market analysis, by country

6.4. Other end users

6.4.1. Market size and forecast, by region
6.4.2. Market analysis, by country

Chapter: 7: BLOOD PLASMA DERIVATIVES MARKET, BY REGION

7.1. Overview

7.1.1. Market size and forecast

7.2. North America

7.2.1. Key market trends, growth factors and opportunities
7.2.2. North America blood plasma derivatives market, by country

7.2.2.1. U.S.

7.2.2.1.1. Market size and forecast, by type
7.2.2.1.2. Market size and forecast, by application
7.2.2.1.3. Market size and forecast, by end user

7.2.2.2. Canada

7.2.2.2.1. Market size and forecast, by type
7.2.2.2.2. Market size and forecast, by application
7.2.2.2.3. Market size and forecast, by end user

7.2.2.3. Mexico

7.2.2.3.1. Market size and forecast, by type
7.2.2.3.2. Market size and forecast, by application
7.2.2.3.3. Market size and forecast, by end user

7.2.3. North America market size and forecast, by type
7.2.4. North America market size and forecast, by application
7.2.5. North America market size and forecast, by end user

7.3. Europe

7.3.1. Key market trends, growth factors and opportunities
7.3.2. Europe market size and forecast, by country

7.3.2.1. Germany

7.3.2.1.1. Market size and forecast, by type
7.3.2.1.2. Market size and forecast, by application
7.3.2.1.3. Market size and forecast, by end user

7.3.2.2. France

7.3.2.2.1. Market size and forecast, by type
7.3.2.2.2. Market size and forecast, by application
7.3.2.2.3. Market size and forecast, by end user

7.3.2.3. UK

7.3.2.3.1. Market size and forecast, by type
7.3.2.3.2. Market size and forecast, by application
7.3.2.3.3. Market size and forecast, by end user

7.3.2.4. Italy

7.3.2.4.1. Market size and forecast, by type
7.3.2.4.2. Market size and forecast, by application
7.3.2.4.3. Market size and forecast, by end user

7.3.2.5. Spain

7.3.2.5.1. Market size and forecast, by type
7.3.2.5.2. Market size and forecast, by application
7.3.2.5.3. Market size and forecast, by end user

7.3.2.6. Rest of Europe

7.3.2.6.1. Market size and forecast, by type
7.3.2.6.2. Market size and forecast, by application
7.3.2.6.3. Market size and forecast, by end user

7.3.3. Europe market size and forecast, by type
7.3.4. Europe market size and forecast, by application
7.3.5. Europe market size and forecast, by end user

7.4. Asia-Pacific

7.4.1. Key market trends, growth factors and opportunities
7.4.2. Asia-Pacific market size and forecast, by country

7.4.2.1. Japan

7.4.2.1.1. Market size and forecast, by type
7.4.2.1.2. Market size and forecast, by application
7.4.2.1.3. Market size and forecast, by end user

7.4.2.2. China

7.4.2.2.1. Market size and forecast, by type
7.4.2.2.2. Market size and forecast, by application
7.4.2.2.3. Market size and forecast, by end user

7.4.2.3. India

7.4.2.3.1. Market size and forecast, by type
7.4.2.3.2. Market size and forecast, by application
7.4.2.3.3. Market size and forecast, by end user

7.4.2.4. Australia

7.4.2.4.1. Market size and forecast, by type
7.4.2.4.2. Market size and forecast, by application
7.4.2.4.3. Market size and forecast, by end user

7.4.2.5. South Korea

7.4.2.5.1. Market size and forecast, by type
7.4.2.5.2. Market size and forecast, by application
7.4.2.5.3. Market size and forecast, by end user

7.4.2.6. Rest of Asia-Pacific

7.4.2.6.1. Market size and forecast, by type
7.4.2.6.2. Market size and forecast, by application
7.4.2.6.3. Market size and forecast, by end user

7.4.3. Asia-Pacific market size and forecast, by type
7.4.4. Asia-Pacific market size and forecast, by application
7.4.5. Asia-Pacific market size and forecast, by end user

7.5. LAMEA

7.5.1. Key market trends, growth factors and opportunities
7.5.2. LAMEA market size and forecast, by country

7.5.2.1. Brazil

7.5.2.1.1. Market size and forecast, by type
7.5.2.1.2. Market size and forecast, by application
7.5.2.1.3. Market size and forecast, by end user

7.5.2.2. Saudi Arabia

7.5.2.2.1. Market size and forecast, by type
7.5.2.2.2. Market size and forecast, by application
7.5.2.2.3. Market size and forecast, by end user

7.5.2.3. South Africa

7.5.2.3.1. Market size and forecast, by type
7.5.2.3.2. Market size and forecast, by application
7.5.2.3.3. Market size and forecast, by end user

7.5.2.4. Rest of LAMEA

7.5.2.4.1. Market size and forecast, by type
7.5.2.4.2. Market size and forecast, by application
7.5.2.4.3. Market size and forecast, by end user

7.5.3. LAMEA market size and forecast, by type
7.5.4. LAMEA market size and forecast, by application
7.5.5. LAMEA market size and forecast, by end user

Chapter: 8: COMPANY PROFILES

8.1. Baxter International Inc.

8.1.1. Company overview
8.1.2. Company snapshot
8.1.3. Operating business segments
8.1.4. Product portfolio
8.1.5. Business performance

8.2. Biotest AG

8.2.1. Company overview
8.2.2. Company snapshot
8.2.3. Operating business segments
8.2.4. Product portfolio
8.2.5. Business performance
8.2.6. Key strategic moves and developments

8.3. CSL Limited

8.3.1. Company overview
8.3.2. Company snapshot
8.3.3. Operating business segments
8.3.4. Product portfolio
8.3.5. Business performance
8.3.6. Key strategic moves and developments

8.4. Fusion Health Care Pvt. Ltd.

8.4.1. Company overview
8.4.2. Company snapshot
8.4.3. Operating business segments
8.4.4. Product portfolio

8.5. Grifols S.A.

8.5.1. Company overview
8.5.2. Company snapshot
8.5.3. Operating business segments
8.5.4. Product portfolio
8.5.5. Business performance
8.5.6. Key strategic moves and developments

8.6. Green Cross Holdings Corporation (Green Cross Corp.)

8.6.1. Company overview
8.6.2. Company snapshot
8.6.3. Operating business segments
8.6.4. Product portfolio
8.6.5. Business performance
8.6.6. Key strategic moves and developments

8.7. LFB SA (LFB Biotechnologies SAS)

8.7.1. Company overview
8.7.2. Company snapshot
8.7.3. Operating business segments
8.7.4. Product portfolio
8.7.5. Business performance
8.7.6. Key strategic moves and developments

8.8. Octapharma AG

8.8.1. Company overview
8.8.2. Company snapshot
8.8.3. Operating business segments
8.8.4. Product portfolio
8.8.5. Business performance
8.8.6. Key strategic moves and developments

8.9. Shire Plc.

8.9.1. Company overview
8.9.2. Company snapshot
8.9.3. Operating business segments
8.9.4. Product portfolio
8.9.5. Business performance
8.9.6. Key strategic moves and developments

8.10. SK chemicals (SK Plasma Co., Ltd.)

8.10.1. Company overview
8.10.2. Company snapshot
8.10.3. Operating business segments
8.10.4. Product portfolio
8.10.5. Business performance

LIST OF TABLES

TABLE 01. GLOBAL BLOOD PLASMA DERIVATIVES MARKET, BY TYPE, 2016-2023 ($MILLION)
TABLE 02. PLASMA-DERIVED ALBUMIN MARKET, BY REGION, 2016-2023 ($MILLION)
TABLE 03. PLASMA-DERIVED FACTOR VIII MARKET, BY REGION, 2016-2023 ($MILLION)
TABLE 04. PLASMA-DERIVED FACTOR IX MARKET, BY REGION, 2016-2023 ($MILLION)
TABLE 05. PLASMA-DERIVED IMMUNOGLOBULINS MARKET, BY REGION, 2016-2023 ($MILLION)
TABLE 06. PLASMA-DERIVED HYPERIMMUNE GLOBULIN MARKET, BY REGION, 2016-2023 ($MILLION)
TABLE 07. OTHERS PLASMA DERIVED PRODUCTS MARKET, BY REGION, 2016-2023 ($MILLION)
TABLE 08. GLOBAL BLOOD PLASMA DERIVATIVES MARKET, BY APPLICATION, 2016-2023 ($MILLION)
TABLE 09. BLOOD PLASMA DERIVATIVES MARKET FOR HEMOPHILIA, BY REGION, 2016-2023 ($MILLION)
TABLE 10. BLOOD PLASMA DERIVATIVES MARKET FOR HYPOGAMMAGLOBULINEMIA, BY REGION, 2016-2023 ($MILLION)
TABLE 11. BLOOD PLASMA DERIVATIVES MARKET FOR IMMUNODEFICIENCY DISEASES, BY REGION, 2016-2023 ($MILLION)
TABLE 12. BLOOD PLASMA DERIVATIVES MARKET FOR VON WILLEBRAND DISEASE, BY REGION, 2016-2023 ($MILLION)
TABLE 13. BLOOD PLASMA DERIVATIVES MARKET FOR OTHER APPLICATIONS, BY REGION, 2016-2023 ($MILLION)
TABLE 14. GLOBAL BLOOD PLASMA DERIVATIVES MARKET, BY END USER, 2016-2023 ($MILLION)
TABLE 15. BLOOD PLASMA DERIVATIVES MARKET FOR HOSPITALS, BY REGION, 2016-2023 ($MILLION)
TABLE 16. BLOOD PLASMA DERIVATIVES MARKET FOR CLINICS, BY REGION, 2016-2023 ($MILLION)
TABLE 17. BLOOD PLASMA DERIVATIVES MARKET FOR OTHER END USERS, BY REGION, 2016-2023 ($MILLION)
TABLE 18. BLOOD PLASMA DERIVATIVES MARKET, BY REGION, 2016-2023 ($MILLION)
TABLE 19. NORTH AMERICA BLOOD PLASMA DERIVATIVES MARKET, BY COUNTRY, 2016-2023 ($MILLION)
TABLE 20. U.S. BLOOD PLASMA DERIVATIVES MARKET, BY TYPE, 2016-2023 ($MILLION)
TABLE 21. U.S. BLOOD PLASMA DERIVATIVES MARKET, BY APPLICATION, 2016-2023 ($MILLION)
TABLE 22. U.S. BLOOD PLASMA DERIVATIVES MARKET, BY END USER, 2016-2023 ($MILLION)
TABLE 23. CANADA BLOOD PLASMA DERIVATIVES MARKET, BY TYPE, 2016-2023 ($MILLION)
TABLE 24. CANADA BLOOD PLASMA DERIVATIVES MARKET, BY APPLICATION, 2016-2023 ($MILLION)
TABLE 25. CANADA BLOOD PLASMA DERIVATIVES MARKET, BY END USER, 2016-2023 ($MILLION)
TABLE 26. MEXICO BLOOD PLASMA DERIVATIVES MARKET, BY TYPE, 2016-2023 ($MILLION)
TABLE 27. MEXICO BLOOD PLASMA DERIVATIVES MARKET, BY APPLICATION, 2016-2023 ($MILLION)
TABLE 28. MEXICO BLOOD PLASMA DERIVATIVES MARKET, BY END USER, 2016-2023 ($MILLION)
TABLE 29. NORTH AMERICA BLOOD PLASMA DERIVATIVES MARKET, BY TYPE, 2016-2023 ($MILLION)
TABLE 30. NORTH AMERICA BLOOD PLASMA DERIVATIVES MARKET, BY APPLICATION, 2016-2023 ($MILLION)
TABLE 31. NORTH AMERICA BLOOD PLASMA DERIVATIVES MARKET, BY END USER, 2016-2023 ($MILLION)
TABLE 32. EUROPE BLOOD PLASMA DERIVATIVES MARKET, BY COUNTRY, 2016-2023 ($MILLION)
TABLE 33. GERMANY BLOOD PLASMA DERIVATIVES MARKET, BY TYPE, 2016-2023 ($MILLION)
TABLE 34. GERMANY BLOOD PLASMA DERIVATIVES MARKET, BY APPLICATION, 2016-2023 ($MILLION)
TABLE 35. GERMANY BLOOD PLASMA DERIVATIVES MARKET, BY END USER, 2016-2023 ($MILLION)
TABLE 36. FRANCE BLOOD PLASMA DERIVATIVES MARKET, BY TYPE, 2016-2023 ($MILLION)
TABLE 37. FRANCE BLOOD PLASMA DERIVATIVES MARKET, BY APPLICATION, 2016-2023 ($MILLION)
TABLE 38. FRANCE BLOOD PLASMA DERIVATIVES MARKET, BY END USER, 2016-2023 ($MILLION)
TABLE 39. UK BLOOD PLASMA DERIVATIVES MARKET, BY TYPE, 2016-2023 ($MILLION)
TABLE 40. UK BLOOD PLASMA DERIVATIVES MARKET, BY APPLICATION, 2016-2023 ($MILLION)
TABLE 41. UK BLOOD PLASMA DERIVATIVES MARKET, BY END USER, 2016-2023 ($MILLION)
TABLE 42. ITALY BLOOD PLASMA DERIVATIVES MARKET, BY TYPE, 2016-2023 ($MILLION)
TABLE 43. ITALY BLOOD PLASMA DERIVATIVES MARKET, BY APPLICATION, 2016-2023 ($MILLION)
TABLE 44. ITALY BLOOD PLASMA DERIVATIVES MARKET, BY END USER, 2016-2023 ($MILLION)
TABLE 45. SPAIN BLOOD PLASMA DERIVATIVES MARKET, BY TYPE, 2016-2023 ($MILLION)
TABLE 46. SPAIN BLOOD PLASMA DERIVATIVES MARKET, BY APPLICATION, 2016-2023 ($MILLION)
TABLE 47. SPAIN BLOOD PLASMA DERIVATIVES MARKET, BY END USER, 2016-2023 ($MILLION)
TABLE 48. REST OF EUROPE BLOOD PLASMA DERIVATIVES MARKET, BY TYPE, 2016-2023 ($MILLION)
TABLE 49. REST OF EUROPE BLOOD PLASMA DERIVATIVES MARKET, BY APPLICATION, 2016-2023 ($MILLION)
TABLE 50. REST OF EUROPE BLOOD PLASMA DERIVATIVES MARKET, BY END USER, 2016-2023 ($MILLION)
TABLE 51. EUROPE BLOOD PLASMA DERIVATIVES MARKET, BY TYPE, 2016-2023 ($MILLION)
TABLE 52. EUROPE BLOOD PLASMA DERIVATIVES MARKET, BY APPLICATION, 2016-2023 ($MILLION)
TABLE 53. EUROPE BLOOD PLASMA DERIVATIVES MARKET, BY END USER, 2016-2023 ($MILLION)
TABLE 54. ASIA-PACIFIC BLOOD PLASMA DERIVATIVES MARKET, BY COUNTRY, 2016-2023 ($MILLION)
TABLE 55. JAPAN BLOOD PLASMA DERIVATIVES MARKET, BY TYPE, 2016-2023 ($MILLION)
TABLE 56. JAPAN BLOOD PLASMA DERIVATIVES MARKET, BY APPLICATION, 2016-2023 ($MILLION)
TABLE 57. JAPAN BLOOD PLASMA DERIVATIVES MARKET, BY END USER, 2016-2023 ($MILLION)
TABLE 58. CHINA BLOOD PLASMA DERIVATIVES MARKET, BY TYPE, 2016-2023 ($MILLION)
TABLE 59. CHINA BLOOD PLASMA DERIVATIVES MARKET, BY APPLICATION, 2016-2023 ($MILLION)
TABLE 60. CHINA BLOOD PLASMA DERIVATIVES MARKET, BY END USER, 2016-2023 ($MILLION)
TABLE 61. INDIA BLOOD PLASMA DERIVATIVES MARKET, BY TYPE, 2016-2023 ($MILLION)
TABLE 62. INDIA BLOOD PLASMA DERIVATIVES MARKET, BY APPLICATION, 2016-2023 ($MILLION)
TABLE 63. INDIA BLOOD PLASMA DERIVATIVES MARKET, BY END USER, 2016-2023 ($MILLION)
TABLE 64. AUSTRALIA BLOOD PLASMA DERIVATIVES MARKET, BY TYPE, 2016-2023 ($MILLION)
TABLE 65. AUSTRALIA BLOOD PLASMA DERIVATIVES MARKET, BY APPLICATION, 2016-2023 ($MILLION)
TABLE 66. AUSTRALIA BLOOD PLASMA DERIVATIVES MARKET, BY END USER, 2016-2023 ($MILLION)
TABLE 67. SOUTH KOREA BLOOD PLASMA DERIVATIVES MARKET, BY TYPE, 2016-2023 ($MILLION)
TABLE 68. SOUTH KOREA BLOOD PLASMA DERIVATIVES MARKET, BY APPLICATION, 2016-2023 ($MILLION)
TABLE 69. SOUTH KOREA BLOOD PLASMA DERIVATIVES MARKET, BY END USER, 2016-2023 ($MILLION)
TABLE 70. REST OF ASIA-PACIFIC BLOOD PLASMA DERIVATIVES MARKET, BY TYPE, 2016-2023 ($MILLION)
TABLE 71. REST OF ASIA-PACIFIC BLOOD PLASMA DERIVATIVES MARKET, BY APPLICATION, 2016-2023 ($MILLION)
TABLE 72. REST OF ASIA-PACIFIC BLOOD PLASMA DERIVATIVES MARKET, BY END USER, 2016-2023 ($MILLION)
TABLE 73. ASIA-PACIFIC BLOOD PLASMA DERIVATIVES MARKET, BY TYPE, 2016-2023 ($MILLION)
TABLE 74. ASIA-PACIFIC BLOOD PLASMA DERIVATIVES MARKET, BY APPLICATION, 2016-2023 ($MILLION)
TABLE 75. ASIA-PACIFIC BLOOD PLASMA DERIVATIVES MARKET, BY END USER, 2016-2023 ($MILLION)
TABLE 76. LAMEA BLOOD PLASMA DERIVATIVES MARKET, BY COUNTRY, 2016-2023 ($MILLION)
TABLE 77. BRAZIL BLOOD PLASMA DERIVATIVES MARKET, BY TYPE, 2016-2023 ($MILLION)
TABLE 78. BRAZIL BLOOD PLASMA DERIVATIVES MARKET, BY APPLICATION, 2016-2023 ($MILLION)
TABLE 79. BRAZIL BLOOD PLASMA DERIVATIVES MARKET, BY END USER, 2016-2023 ($MILLION)
TABLE 80. SAUDI ARABIA BLOOD PLASMA DERIVATIVES MARKET, BY TYPE, 2016-2023 ($MILLION)
TABLE 81. SAUDI ARABIA BLOOD PLASMA DERIVATIVES MARKET, BY APPLICATION, 2016-2023 ($MILLION)
TABLE 82. SAUDI ARABIA BLOOD PLASMA DERIVATIVES MARKET, BY END USER, 2016-2023 ($MILLION)
TABLE 83. SOUTH AFRICA BLOOD PLASMA DERIVATIVES MARKET, BY TYPE, 2016-2023 ($MILLION)
TABLE 84. SOUTH AFRICA BLOOD PLASMA DERIVATIVES MARKET, BY APPLICATION, 2016-2023 ($MILLION)
TABLE 85. SOUTH AFRICA BLOOD PLASMA DERIVATIVES MARKET, BY END USER, 2016-2023 ($MILLION)
TABLE 86. REST OF LAMEA BLOOD PLASMA DERIVATIVES MARKET, BY TYPE, 2016-2023 ($MILLION)
TABLE 87. REST OF LAMEA BLOOD PLASMA DERIVATIVES MARKET, BY APPLICATION, 2016-2023 ($MILLION)
TABLE 88. REST OF LAMEA BLOOD PLASMA DERIVATIVES MARKET, BY END USER, 2016-2023 ($MILLION)
TABLE 89. LAMEA BLOOD PLASMA DERIVATIVES MARKET, BY TYPE, 2016-2023 ($MILLION)
TABLE 90. LAMEA BLOOD PLASMA DERIVATIVES MARKET, BY APPLICATION, 2016-2023 ($MILLION)
TABLE 91. LAMEA BLOOD PLASMA DERIVATIVES MARKET, BY END USER, 2016-2023 ($MILLION)
TABLE 92. BAXTER: COMPANY SNAPSHOT
TABLE 93. BAXTER: OPERATING SEGMENTS
TABLE 94. BAXTER: PRODUCT PORTFOLIO
TABLE 95. BIOTEST: COMPANY SNAPSHOT
TABLE 96. BIOTEST: OPERATING SEGMENTS
TABLE 97. BIOTEST: OPERATING SEGMENT
TABLE 98. CSL: COMPANY SNAPSHOT
TABLE 99. CSL: PRODUCT SEGMENTS
TABLE 100. CSL: PRODUCT PORTFOLIO
TABLE 101. FUSION HEALTHCARE: COMPANY SNAPSHOT
TABLE 102. FUSION HEALTHCARE: OPERATING DIVISION
TABLE 103. FUSION HEALTHCARE: PRODUCT PORTFOLIO
TABLE 104. GRIFOLS: COMPANY SNAPSHOT
TABLE 105. GRIFOLS: OPERATING SEGMENTS
TABLE 106. GRIFOLS: PRODUCT PORTFOLIO
TABLE 107. GREEN CROSS: COMPANY SNAPSHOT
TABLE 108. GREEN CROSS: OPERATING SEGMENTS
TABLE 109. GREEN CROSS: PRODUCT PORTFOLIO
TABLE 110. LFB: COMPANY SNAPSHOT
TABLE 111. LFB: PRODUCT SEGMENTS
TABLE 112. LFB: PRODUCT PORTFOLIO
TABLE 113. OCTAPHARMA: COMPANY SNAPSHOT
TABLE 114. OCTAPHARMA: PRODUCT SEGMENTS
TABLE 115. OCTAPHARMA: PRODUCT PORTFOLIO
TABLE 116. SHIRE: COMPANY SNAPSHOT
TABLE 117. SHIRE: PRODUCT PORTFOLIO
TABLE 118. SK CHEMICALS: COMPANY SNAPSHOT
TABLE 119. SK CHEMICALS: OPERATING SEGMENTS
TABLE 120. SK CHEMICALS: PRODUCT PORTFOLIO

LIST OF FIGURES

FIGURE 01. BLOOD PLASMA DERIVATIVES MARKET SEGMENTATION
FIGURE 02. TOP INVESTMENT POCKETS
FIGURE 03. TOP WINNING STRATEGIES, BY YEAR, 2015-2018*
FIGURE 04. TOP WINNING STRATEGIES, BY DEVELOPMENT, 2015-2018* (%)
FIGURE 05. TOP WINNING STRATEGIES, BY COMPANY, 2015-2018*
FIGURE 06. TOP PLAYER POSITIONING, 2016
FIGURE 07. PERCENTAGE OF PEOPLE WITH HEMOPHILIA A IN THE U.S. IN 2016, BY AGE GROUP
FIGURE 08. IMPACT ANALYSES
FIGURE 09. COMPARATIVE ANALYSIS OF PLASMA-DERIVED ALBUMIN MARKET, 2016-2023 ($MILLION)
FIGURE 10. COMPARATIVE ANALYSIS OF PLASMA-DERIVED FACTOR VIII MARKET, 2016-2023 ($MILLION)
FIGURE 11. COMPARATIVE ANALYSIS OF PLASMA DERIVED FACTOR IX MARKET, 2016-2023 ($MILLION)
FIGURE 12. COMPARATIVE ANALYSIS OF PLASMA-DERIVED IMMUNOGLOBULIN MARKET, 2016-2023 ($MILLION)
FIGURE 13. COMPARATIVE ANALYSIS OF PLASMA DERIVED HYPERIMMUNE GLOBULIN MARKET, 2016-2023 ($MILLION)
FIGURE 14. COMPARATIVE ANALYSIS OF OTHERS PLASMA-DERIVED PRODUCTS MARKET, 2016-2023 ($MILLION)
FIGURE 15. COMPARATIVE ANALYSIS OF BLOOD PLASMA DERIVATIVES FOR HEMOPHILIA MARKET, 2016-2023 ($MILLION)
FIGURE 16. COMPARATIVE ANALYSIS OF BLOOD PLASMA DERIVATIVES FOR HYPOGAMMAGLOBULINEMIA MARKET, 2016-2023 ($MILLION)
FIGURE 17. COMPARATIVE ANALYSIS OF BLOOD PLASMA DERIVATIVES FOR IMMUNODEFICIENCY DISEASES MARKET, 2016-2023 ($MILLION)
FIGURE 18. COMPARATIVE ANALYSIS OF BLOOD PLASMA DERIVATIVES FOR VON WILLEBRAND DISEASE MARKET, 2016-2023 ($MILLION)
FIGURE 19. COMPARATIVE ANALYSIS OF BLOOD PLASMA DERIVATIVES MARKET FOR OTHER APPLICATIONS, 2016-2023 ($MILLION)
FIGURE 20. COMPARATIVE ANALYSIS OF BLOOD PLASMA DERIVATIVES FOR HOSPITALS MARKET, 2016-2023 ($MILLION)
FIGURE 21. COMPARATIVE ANALYSIS OF BLOOD PLASMA DERIVATIVES FOR CLINICS MARKET, 2016-2023 ($MILLION)
FIGURE 22. COMPARATIVE ANALYSIS OF BLOOD PLASMA DERIVATIVES FOR OTHER END USER MARKET, 2016-2023 ($MILLION)
FIGURE 23. PERCENTAGE OF PEOPLE WITH HEMOPHILIA B IN THE U.S. IN 2016, BY AGE GROUP
FIGURE 24. AGE DISTRIBUTION OF THE UK POPULATION, 2006 TO 2046 (IN PERCENTAGE)
FIGURE 25. BAXTER: NET SALES, 2015-2017 ($MILLION)
FIGURE 26. BAXTER: REVENUE SHARE BY SEGMENT, 2017 (%)
FIGURE 27. BAXTER: REVENUE SHARE BY GEOGRAPHY, 2017 (%)
FIGURE 28. BIOTEST: NET SALES, 2015-2017 ($MILLION)
FIGURE 29. BIOTEST: REVENUE SHARE BY SEGMENT, 2017 (%)
FIGURE 30. BIOTEST: REVENUE SHARE BY GEOGRAPHY, 2017 (%)
FIGURE 31. CSL: NET SALES, 2015-2017 ($MILLION)
FIGURE 32. CSL: REVENUE SHARE BY SEGMENT, 2017 (%)
FIGURE 33. CSL: REVENUE SHARE BY GEOGRAPHY, 2017 (%)
FIGURE 34. GRIFOLS: NET SALES, 2014-2016 ($MILLION)
FIGURE 35. GRIFOLS: REVENUE SHARE BY SEGMENT, 2016 (%)
FIGURE 36. GRIFOLS: REVENUE SHARE BY GEPGRAPHY, 2016 (%)
FIGURE 37. GREEN CROSS: NET SALES, 2014-2015 ($MILLION)
FIGURE 38. GREEN CROSS: REVENUE SHARE BY SEGMENT, 2016 (%)
FIGURE 39. GREEN CROSS: REVENUE SHARE BY GEOGRAPHY, 2016 (%)
FIGURE 40. LFB: NET SALES, 2014-2016 ($MILLION)
FIGURE 41. LFB: REVENUE SHARE BY PRODUCT SEGMENT, 2016 (%)
FIGURE 42. LFB: REVENUE SHARE BY GEOGRAPHY, 2016 (%)
FIGURE 43. OCTAPHARMA: NET SALES, 2015-2017 ($MILLION)
FIGURE 44. SHIRE: NET SALES, 2015-2017 ($MILLION)
FIGURE 45. SHIRE: REVENUE SHARE BY PRODUCT, 2017 (%)
FIGURE 46. SHIRE: REVENUE SHARE BY GEOGRAPHY, 2017 (%)
FIGURE 47. SK CHEMICALS: NET SALES, 2014-2016 ($MILLION)
FIGURE 48. SK CHEMICALS: REVENUE SHARE BY SEGMENT, 2016 (%)

 

Blood plasma is liquid component of blood in which blood cells are suspended. It comprises more than 100 different proteins, including albumin, immunoglobulins, clotting factors, fibrinogen, and protease inhibitors. Plasma derivatives are obtained from human plasma by fractionation that are further used to treat number of disorders.

Upsurge in number of patients suffering from life-threatening diseases such as hemophilia and immunodeficiency disorders is the major factor driving the growth of the global blood plasma derivatives market. Other factors such as high adoption of blood plasma derivatives products, rise in geriatric population, and increase in number of blood & plasma donation are expected to have a significant impact on the market growth. However, factors such as expensive plasma derivative-based therapy and post-operative risks associated with donated plasma derivatives hamper the market growth.

The use of blood plasma derivatives is the highest in North America, owing to the presence of large patient population and high adoption of plasma derivatives, followed by Europe and Asia-Pacific. In addition, blood plasma derivative providers and distributors have focused on expanding their presence in the emerging economies, which in turn is anticipated to drive the market growth.

 

PURCHASE OPTIONS

* Taxes/Fees, If applicable will be
added during checkout. All prices in USD.

Reach out to us

Call us on
( U.S. - Canada toll free )
+1-800-792-5285,    Int'l : +1-503-894-6022
Drop us an email at
help@alliedmarketresearch.com

Send Enquiry

Request sample

OR

Purchase Full Report of
Blood Plasma Derivatives Market- Global Opportunity Analysis and Industry Forecast, 2016-2023

  • Online Only
  • $3456
  • Online cloud Access only
  • Restected Print, copy, paste,download
  • Read Only
  • 20% free customization (Pre-Sale)
  •   Free quartery industry update
  •   Free report update (Within 180 days)
  •   Subscription Model Sign In
  • Data Pack
  • $3840
  • Restricted to one authorized users
  • One print only
  • Available in Excel
  • 20% free customization (Pre-Sale)
  •   Free quartery industry update
  •   Free report update (Within 180 days)
  •   Subscription Model Sign In
  • Single User
  • $5370
  • Restricted to one authorized users
  • One print only
  • Available in PDF
  • 20% free customization (Pre-Sale)
  •   Free quartery industry update
  •   Free report update (Within 180 days)
  •   Subscription Model Sign In
  • Five User
  • $6450
  • Limited to 5 authorized users
  • Print Upto Five Copies
  • Available in PDF
  • 20% free customization (Pre-Sale)
  •   Free quartery industry update
  •   Free report update (Within 180 days)
  •   Subscription Model Sign In
  • Enterprice
    License/PDF

  • $8995
  • Unlimited within company/enterprise
  • Unlimited within company/enterprise
  • Available in PDF
  • 20% free customization (Pre-Sale)
  • Free quartery industry update
  • Free report update (Within 180 days)
  • Subscription Model Sign In

*Taxes/Fees, if applicable will be added during checkout. All prices in USD

 

HAVE QUESTIONS?
SPEAK WITH ANALYST

 
 

FREQUENTLY ASKED
QUESTIONS?

 
 

DID YOU MISS ANYTHING?
DO YOU HAVE SPECIFIC REQUIREMENTS?

 
 
 

Why Allied Market Research

 

Infallible Methodology

To ensure high level data integrity, accurate analysis and impeccable forecasts

Analyst Support

For complete satisfaction

Customization

On-demand customization of scope of the report to exactly meet your needs

TARGETED MARKET VIEW

Targeted market view to provide pertinent information and save time of readers

 
 

Featured Reports

 
 

Featured Readings

 

Get Fresh content delivered

Get insights on topics that are crucial for your business. Stay abreast of your interest areas.

 
Get Industry Data Alerts
 

Access reports on all emerging
market of Life Sciences on Knowledge Tree Platform
Free Demo